Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.

doi:10.1038/clpt.2012.13

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.

Clinical pharmacology and therapeutics - 1 Jul 2012

Tarkiainen E K, Backman J T, Neuvonen M, Neuvonen P J, Schwab M, Niemi M

Abstract excerpt

Bioactivation of the antiviral agent oseltamivir to active oseltamivir carboxylate is catalyzed by carboxylesterase 1 (CES1). After the screening of 860 healthy Finnish volunteers for the CES1 c.428G>A (p.Gly143Glu, rs121912777) polymorphism, a pharmacokinetic study with 75 mg oseltamivir was carried out in c.428G>A carriers and noncarriers. Heterozygous c.428GA carriers (n = 9) had 18% larger values of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboxylic Ester Hydrolases

Share to Drug Monitoring

Share to Influenza A virus

Share to Influenza B virus

Share to Influenza, Human

Share to Oseltamivir

Share to Prodrugs

Source

Open in PubMed

Identifiers

PMID: 22588607
DOI: 10.1038/clpt.2012.13

Genes

CES1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.PMID 22588607Read ↗

The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.Semantic proximity Read ↗

The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans.Semantic proximity Read ↗

Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.Semantic proximity Read ↗

Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir DispositionSemantic proximity Read ↗

A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment.Semantic proximity Read ↗

Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril.Semantic proximity Read ↗

Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.Semantic proximity Read ↗

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.Semantic proximity Read ↗

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.Semantic proximity Read ↗

Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report.Semantic proximity Read ↗

Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.